BCWM
ONCY

Ball & Co Wealth Management’s Oncolytics Biotech ONCY Stock Holding History

Ball & Co Wealth Management’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38,253
Closed -$32K – 81
2026
Q1 		$32K Hold
38,253
– – 0.03% 48
2025
Q4 		$33K Hold
38,253
– – 0.02% 45
2025
Q3 		$53K Buy
38,253
+1,967
+5% +$2.2K 0.04% 46
2025
Q2 		$28K Hold
36,286
– – 0.03% 41
2025
Q1 		$19K Buy
36,286
+31,893
+726% +$23.3K 0.02% 42
2024
Q4 		$4K Buy
+4,393
New +$4.57K ﹤0.01% 54

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.71B AUM 30.33% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAS
Professional Advisory Services Vero Beach, Florida $836M AUM 25.79% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Ball & Co Wealth Management's ONCY Position: Q2 2026 in Review

Ball & Co Wealth Management sold out of Oncolytics Biotech (ONCY) in Q2 2026, closing a stake of 38,253 shares — an estimated $32K sold.

Ball & Co Wealth Management first reported a position in ONCY in Q4 2024 and held it in 6 quarters. The position peaked at $53K in Q3 2025. 24 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • Ball & Co Wealth Management reported no remaining Oncolytics Biotech position as of Q2 2026 after selling out during the quarter.
  • Ball & Co Wealth Management sold 38,253 Oncolytics Biotech shares in Q2 2026, an estimated $32K.
  • Ball & Co Wealth Management first reported a position in Oncolytics Biotech in Q4 2024 and held it in 6 quarters.
  • Ball & Co Wealth Management's Oncolytics Biotech position peaked at $53K in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Ball & Co Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.